Literature DB >> 4015372

In situ femoropopliteal and infrapopliteal bypass. Two-year experience.

W I Carney, A Balko, M S Barrett.   

Abstract

We describe 83 in situ femoropopliteal and infrapopliteal artery bypass grafts. The in situ technique involved the valve incision method using scissors, the valvulotome (Leather), and a modified valve cutter (Hall). Arteriovenous fistulae were detected intraoperatively by angiography and/or the Doppler method and ligated. The operative indications were rest pain, ulcer, and gangrene in 88% of cases, and claudication in 7.2%. The mean preoperative ankle pressure was 61.3 mm Hg and the ankle-brachial index was 0.43. The mean postoperative ankle pressure was 125.3 mm Hg and the ankle-brachial index was 0.97. The vein utilization rate was 96%. One-year patency for popliteal anastomoses was 85.7%, for peroneal anastomoses it was 100%, and for infrapopliteal anastomoses it was 89.6%. The data suggest that the practicing vascular surgeon can adopt the in situ technique and can expect high graft patency rates even in limb salvage situations with poor distal outflow.

Entities:  

Mesh:

Year:  1985        PMID: 4015372     DOI: 10.1001/archsurg.1985.01390310050011

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Resurrection of the in situ saphenous vein bypass. 1000 cases later.

Authors:  R P Leather; D M Shah; B B Chang; J L Kaufman
Journal:  Ann Surg       Date:  1988-10       Impact factor: 12.969

2.  The evolution of morphologic and biomechanical changes in reversed and in-situ vein grafts.

Authors:  R P Cambria; J Megerman; D C Brewster; D F Warnock; J Hasson; W M Abbott
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

3.  Reversed vein bypass to infrapopliteal arteries. Modern results are superior to or equivalent to in-situ bypass for patency and for vein utilization.

Authors:  L M Taylor; J M Edwards; E S Phinney; J M Porter
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.